Blue Sky: Glaucus claims ‘fundamentally flawed and materially misleading’

Australian GP hits back at claims from US short-seller that it has misled investors, casting doubt on Glaucus’ research methods and findings.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this